Juno Therapeutics, Inc.
JUNO
JUNO was delisted on the 5th of March, 2018.
158 hedge funds and large institutions have $2.34B invested in Juno Therapeutics, Inc. in 2016 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 52 increasing their positions, 45 reducing their positions, and 38 closing their positions.
90% more call options, than puts
Call options by funds: $46.6M | Put options by funds: $24.6M
16% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 45
3% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 38
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
1% less funds holding
Funds holding: 160 → 158 (-2)
11% less capital invested
Capital invested by funds: $2.61B → $2.34B (-$275M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$371M |
| 2 |
Mitsubishi UFJ Trust & Banking
Tokyo,
Japan
|
+$34.6M |
| 3 |
Morgan Stanley
New York
|
+$34.4M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$17.5M |
| 5 |
Millennium Management
New York
|
+$8.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Crestline Management
Fort Worth,
Texas
|
-$300M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$55.3M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
-$40.8M |
| 4 |
BAMCO Inc
New York
|
-$8.79M |
| 5 |
Goldman Sachs
New York
|
-$7.96M |
JUNO Hedge Fund Activity: Q1 2016 in Review
158 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Juno Therapeutics, Inc. (JUNO) for Q1 2016, worth a combined $2.34B — down 11% from $2.61B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new JUNO positions and 38 closed out — a net gain of 1 holder — while 52 added to existing stakes and 45 trimmed.
The largest buyer was Baillie Gifford & Co, adding an estimated $371M. The largest seller was Crestline Management, cutting an estimated $300M.
- 158 institutional investors held Juno Therapeutics, Inc. (JUNO) as of Q1 2016, down from 160 in Q4 2015.
- Funds reported $2.34B of Juno Therapeutics, Inc. stock for Q1 2016, down 11% quarter-over-quarter.
- 39 funds opened new Juno Therapeutics, Inc. positions in Q1 2016 and 38 closed out, a net change of +1 holder.
- The largest Juno Therapeutics, Inc. buyer in Q1 2016 was Baillie Gifford & Co, an estimated $371M added.
- The largest Juno Therapeutics, Inc. seller in Q1 2016 was Crestline Management, an estimated $300M sold.
Based on aggregated 13F filings for Q1 2016.